Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
136.01
-8.42 (-5.83%)
At close: Nov 2, 2026, 4:00 PM EST
137.00
+0.99 (0.73%)
Pre-market: Nov 3, 2026, 4:32 AM EST
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Axsome Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $276.33. The average 1-year stock price forecast is 103.17% higher than the current stock price, while the lowest is $238 (+74.99%) and the highest is $380 (+179.39%).
Price Target: $276.33 (+103.17%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 18 | 18 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 21 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $247 → $249 | Hold | Reiterates | $247 → $249 | +83.07% | Nov 3, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $276 → $264 | Buy | Reiterates | $276 → $264 | +94.10% | Nov 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $295 → $273 | Buy | Maintains | $295 → $273 | +100.72% | Nov 3, 2026 |
| UBS | UBS | Buy Maintains $256 → $239 | Buy | Maintains | $256 → $239 | +75.72% | Nov 3, 2026 |
| Jefferies | Jefferies | Buy Reiterates $380 → $305 | Buy | Reiterates | $380 → $305 | +124.25% | Nov 2, 2026 |
Financial Forecast
Revenue This Year
956.04M
from 638.50M
Increased by 49.73%
Revenue Next Year
1.47B
from 956.04M
Increased by 53.54%
EPS This Year
-2.24
from -3.47
EPS Next Year
4.20
from -2.24
EPS and Forward PE are based on non-GAAP adjusted numbers.